Investment area
Growth Investments
Region
Europe
Date of investment
April 2020
Exscientia is a pharmatech company and the first to automate drug discovery, generating its own data before combining the analytical power of AI with the creativity and expertise of our world-class scientists. This allows Exscientia to shorten the pre-clinical drug discovery stage by at least three-quarters and, in turn, substantially accelerate the delivery of new treatments.
Contact
Robert Ghenchev
Managing Partner
Departments: Growth Investments, Life Sciences Operating Committee, Novo Holdings US Inc.
Robert joined Novo Holdings in January 2018 and serves as a Managing partner and head of Growth Investments.
Before joining Novo Holdings, Robert was a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the Healthcare Industry. Prior to Moelis, Robert was part of the UK Mergers & Acquisitions team at Deutsche Bank in London.
Robert holds a J.Hons. B.A. degree in Finance and Economics from McGill University and a M.Sc. degree in Financial Economics from the University of Oxford.
Contact
Thomas Jacobsen
Vice President
Departments: Growth Investments, Novo Holdings US Inc.
Thomas joined Novo Holdings A/S in October 2017 as an Associate in Growth Investments. He participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments.
Prior to joining Novo Holdings A/S, Thomas worked as an Analyst at Moelis & Co in London. During this time, Thomas mainly focused on M&A transactions across a broad range of sectors.
Thomas holds a BSc in International Business and Politics and an MSc in Finance and Investments from Copenhagen Business School.
Contact
Helen Gaffney
Partner
Department: Principal Investments
Helen joined Novo Holdings A/S in October 2018 in Principal Investments. She participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments.
Prior to joining Novo Holdings A/S, Helen worked as an investment professional with the private equity firm OpCapita in London. During this time, she worked actively with existing portfolio companies as well as assessing new acquisition opportunities across Europe. Before this, Helen worked as a mergers and acquisitions generalist at Moelis & Company in London.
Helen holds an MBA from Copenhagen Business School and a BA degree in Natural Sciences from the University of Cambridge.
